- Home
- JBTM vs SRRK Comparison
JBTM vs SRRK Comparison
Compare JBTM & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBTM
- SRRK
- Stock Information
- Founded
- JBTM 1994
- SRRK 2012
- Country
- JBTM United States
- SRRK United States
- Employees
- JBTM N/A
- SRRK N/A
- Industry
- JBTM
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JBTM
- SRRK Health Care
- Exchange
- JBTM Nasdaq
- SRRK Nasdaq
- Market Cap
- JBTM 4.0B
- SRRK 4.2B
- IPO Year
- JBTM N/A
- SRRK 2018
- Fundamental
- Price
- JBTM $122.18
- SRRK $40.85
- Analyst Decision
- JBTM
- SRRK Strong Buy
- Analyst Count
- JBTM 0
- SRRK 7
- Target Price
- JBTM N/A
- SRRK $40.43
- AVG Volume (30 Days)
- JBTM 956.7K
- SRRK 955.9K
- Earning Date
- JBTM 02-21-2025
- SRRK 11-12-2024
- Dividend Yield
- JBTM 0.33%
- SRRK N/A
- EPS Growth
- JBTM N/A
- SRRK N/A
- EPS
- JBTM 5.38
- SRRK N/A
- Revenue
- JBTM $1,693,000,000.00
- SRRK N/A
- Revenue This Year
- JBTM N/A
- SRRK N/A
- Revenue Next Year
- JBTM N/A
- SRRK N/A
- P/E Ratio
- JBTM $27.72
- SRRK N/A
- Revenue Growth
- JBTM 1.93
- SRRK N/A
- 52 Week Low
- JBTM $82.64
- SRRK $6.76
- 52 Week High
- JBTM $132.69
- SRRK $46.19
- Technical
- Relative Strength Index (RSI)
- JBTM N/A
- SRRK 49.35
- Support Level
- JBTM N/A
- SRRK $42.55
- Resistance Level
- JBTM N/A
- SRRK $46.13
- Average True Range (ATR)
- JBTM 0.00
- SRRK 2.46
- MACD
- JBTM 0.00
- SRRK -0.89
- Stochastic Oscillator
- JBTM 0.00
- SRRK 17.33
About JBTM JBT Marel Corporation
John Bean Technologies Corp is a food tech business that provides both customized and turnkey industrial solutions for the food and beverage industry, including a large variety of protein processing and packaging solutions, as well as fruit and juice extraction and ready-to-eat solutions.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.